<DOC>
	<DOCNO>NCT01388764</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , effect L-Arginine muscle boys dystrophinopathy corticosteroid . Specifically , see L-arginine reduces muscle signal abnormality MRI do pre post 30 day L-arginine administration .</brief_summary>
	<brief_title>Safety , Tolerability Effects L-Arginine Boys With Dystrophinopathy Corticosteroids</brief_title>
	<detailed_description>Dystrophinopathy muscular dystrophy ( include Duchenne Becker 's Muscular Dystrophy ) lethal muscle disorder result defect gene dystrophin , structural protein require maintain muscle integrity . Absence functional dystrophin leave muscle membrane vulnerable damage contraction . This damage exacerbate inflammatory response lead myofiber necrosis . L-arginine widely available dietary supplement amino acid postulate affect dystrophinopathy several favorable way : upregulation utrophin , vasodilation muscle via nitric oxide , enhance synthesis creatine , increase level growth hormone . We hypothesize administration L-arginine may increase level creatine growth hormone turn reduce extent myofiber damage patient dystrophinopathy</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Confirmation diagnosis dystrophinopathy , document clinical exam dystrophin DNA mutation analysis Ambulatory male subject age 711 year Stable dosage corticosteroid 3 month prior entry ( Screening/Baseline Day 0 ) treatment period Able follow instruction give assent Able complete nonsedated MR Presence metallic orthopedic hardware lower extremity could affect MRI/MRS measurement Routine MRI exclusion criterion presence pacemaker , cochlear implant , cerebral aneurysm clip Subjects capable cooperate MR examination Known hypersensitivity Larginine Exposure another investigational agent , investigational supplement , growth hormone within 3 month prior entry ( Screening/Baseline Day 0 ) treatment period Subjects must take Larginine least 4 week prior entry ( Day 0 ) Subjects nonambulatory daytime ventilatory dependence</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>L-arginine supplement study</keyword>
</DOC>